Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG001 plus chemotherapy in advanced cervical cancer
NCT05715840Phase 3Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of PBI-1308 in Cervical Cancer (CC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
PBI-1308
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05715840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715840.